Showing 4351-4360 of 8735 results for "".
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Vitals Report: National Average Wait Time Down Nearly 10% since 2009https://practicaldermatology.com/news/vitals-report-national-average-wait-time-down-nearly-10-since-2009/2458630/When it comes to waiting for a doctor’s appointment, most patients are waiting 19 minutes, 19 seconds, according to Vitals 7th annual wait time report This is down nearly 10 percent from the average 21 minutes and 18 seconds patients once sp
- Take That, Melanoma! New Patch Delivers Anti-PD-1 Antibodies Directly to Skin Cancerhttps://practicaldermatology.com/news/take-that-melanoma-new-patch-delivers-anti-pd-1-antibodies-directly-to-skin-cancer/2458633/A new patch embedded with microneedles may deliver anti-PD-1 antibodies directly to the site of melanoma, according to a study in Nano Letters. In animal studies, the technique more effectively targeted
- New System Depicts Skin Regeneration in Technicolorhttps://practicaldermatology.com/news/new-system-depicts-skin-regeneration-in-technicolor/2458638/Thanks to a genetically engineered line of technicolor zebrafish, researchers can now visualize skin regeneration at high resolution in real time. Many available methods rely on samples that are "snapshots" of cell growth and movement, but the new system, called Skinbow, c
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- StriVectin® Taps Beauty Vet Joan Malloy As New CEOhttps://practicaldermatology.com/news/strivectin-taps-beauty-vet-joan-malloy-as-new-ceo/2458650/Congrats! Joan Malloy is the new Chief Executive Officer of StriVectin®. For the past six years, Ms. Malloy served as CEO/President of Alterna Haircare. Prior to Alterna, she held senior marketing positions at Fre
- Estée Lauder's Newest Collection Embraces Gen Yhttps://practicaldermatology.com/news/este-lauders-newest-collection-embraces-gen-y/2458652/Estee Lauder’s latest collection is all about the millennials. Fronted by guest editors Kendall Jenner and Irene Kim, the Estée Edit by Estée Lauder comprises 82 makeup and skincare products. The collection is inspired by Estée&rs
- APP® Membership Now Has More Rewards: Three Syneron Candela Platformshttps://practicaldermatology.com/news/app-membership-now-has-more-rewards-three-syneron-candela-platforms/2458655/Syneron Medical Ltd. and Allergan plc are joining forces to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan Partner Privileges® (APP®</
- New from Olay: Regenerist Micro-Sculpting Cream with SPF 30https://practicaldermatology.com/news/new-from-olay-regenerist-micro-sculpting-cream-with-spf-30/2458657/Olay introduced the newest member of the Regenerist family -- Regenerist Micro-Sculpting Cream with SPF 30 -- at the annual meeting of the American Academy of Dermatology in Washington, DC. Several studies presented here helped lay the groundw
- Cipher Pharmaceuticals Appoints New President and General Manager of US Businesshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-new-president-and-general-manager-of-us-business/2458662/Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to